| Price | 220.00p on 28-01-2026 at 19:40:06 |
|---|---|
| Change | -1.00p -0.45% |
| Buy | 221.00p |
| Sell | 216.00p |
| Last Trade: | Buy 114.00 at 220.00p |
| Day's Volume: | 30,920 |
| Last Close: | 220.00p |
| Open: | 222.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 220.00p - 222.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.89b |
| VWAP: | 220.09287p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 114 | 220.00p | Suspected BUY Trade |
16:35:29 - 28-Jan-26 |
| Buy* | 1 | 221.00p | SI Trade |
16:22:30 - 28-Jan-26 |
| Buy* | 500 | 220.245p | Ordinary |
16:11:58 - 28-Jan-26 |
| Sell* | 285 | 220.00p | Automatic Execution |
13:53:03 - 28-Jan-26 |
| Buy* | 3,500 | 221.758p | Ordinary |
13:28:01 - 28-Jan-26 |
| Buy* | 2,705 | 221.76p | Ordinary |
12:31:16 - 28-Jan-26 |
| Buy* | 1 | 225.00p | SI Trade |
12:09:05 - 28-Jan-26 |
| Unknown* | 0 | 225.00p | SI Trade |
12:09:05 - 28-Jan-26 |
| Buy* | 1 | 225.00p | SI Trade |
12:09:05 - 28-Jan-26 |
| Sell* | 1,500 | 222.00p | Automatic Execution |
12:09:05 - 28-Jan-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
